von Tobias Borgers | Aug. 16, 2021 | Frewitt
CRISPR technology, a gene editing tool that can be used to splice and alter the DNA inside a cell, has for years been hailed as the future of genetic disease medicine. However, despite its vast therapeutic potential, the technology does have its limitations; while...
von Tobias Borgers | Aug. 16, 2021 | Frewitt
Big data and artificial intelligence (AI) have the potential to improve clinical efficiency and drug discovery by decoding large data sets into actionable insights. Over the next two years, big data and AI will be the most disruptive influences in the pharma sector...
von Tobias Borgers | Juli 21, 2021 | Frewitt
Covid-19 has forced pharmaceutical salespeople out of the office and on to Zoom, a drastic change to the in-person meetings with clinicians that reps have traditionally relied on. This move, artificial intelligence (AI) company ODAIA estimates, has cost them access to...
von Tobias Borgers | Juli 20, 2021 | Frewitt
When his daughter was hospitalised at birth, Omnicell founder and CEO Randall Lipps observed how inefficiently medical supplies were managed. Notably, he found that nurses were prevented from spending time directly caring for patients because they were too busy drug...
von Tobias Borgers | Juli 15, 2021 | Frewitt
Life sciences investor Novo Holdings will acquire early drug development services platform provider, Altasciences, both groups have announced. Altasciences has grown in the past decade and now operates across six facilities in the US and Canada, employing over 1,300...
von Tobias Borgers | März 26, 2021 | Frewitt
AstraZeneca has signed a definitive agreement to acquire global biopharmaceutical company Alexion Pharmaceuticals for $39bn or $175 a share. According to the agreement, Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares...
